BioSpace2d
‘There’s Only One Semaglutide’: Novo CEO Admits Compounders Are Hurting Weight Loss Business
Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...
Semaglutide and Tirzepatide off FDA shortage list: What does this mean for weight loss drug access?
The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs ...
ConsumerAffairs3d
Tirzepatide vs. semaglutide for weight loss
Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...
Healthline11d
Compounding Pharmacies to Stop Making Ozempic, Zepound Knockoffs: What to Know
The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Wegovy sales took a hit this year. Novo's CEO blames off-brand competition
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or ...
Health.com4d
Study Offers More Evidence That Ozempic Could Cause Hair Loss
Stephanie Anderson Witmer is a freelance journalist based in Pennsylvania. Her work has been published in other top magazines and digital publications, including Prevention, Good Housekeeping ...
Nasdaq4d
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration ... of GLP-1 therapy “Products containing semaglutide generated $25 billion in 2024 and demand ...